Moving from “Wealth = Health” to “Health = Wealth”: building value-based healthcare financing models that deliver equitable access in Asia-Pacific

This update provides key takeaways from one of the expert sessions at the Zuellig Pharma Summit 2022, ‘Building a Healthier Asia: empowering more equitable access to healthcare innovation’. Zuellig Pharma and Knowledge Partner, PRMA Consulting, are pleased to share this summary from the post-summit report to contribute to raising awareness and progressing the conversation on enhancing access to healthcare in the Asia-Pacific region.

How different healthcare systems in the Asia-Pacific region are evaluating and financing the introduction of innovative medicines

During this session, expert speakers discussed how different healthcare systems are evaluating and financing the introduction of innovative medicines and other new technologies that can improve patient outcomes and support equitable access.

Speakers:

Moderator:

Key takeaways:

• In single-payer systems such as Taiwan, innovative models have been implemented to improve patient care, such as the use of cloud storage for patient medical data, reimbursement framework to validate the real-world benefits of new treatments, and value based payment model enabled through analysis of big data from TW NHI Research Database.

• In Singapore, the recent Healthier SG policy has led to more investment in preventive health to support a higher quality of life and control cost inflation.

• Private organizations, such as pharmaceutical companies, expressed the desire to be viewed by governments more as “partners” than “vendors”, and encouraged transparent discussions that could give rise to new sustainable financing models to improve patient access to innovative treatments.

• Innovative financing models are even more critical in emerging markets where access to basic healthcare for all remains a high priority.

  • To prevent over-burdening the healthcare system, value-based pricing model can be used to support patient access to new treatments.

• The role of insurance companies is critical in filling the healthcare funding gaps that governments are unable to cover due to limited budgets.

• Employers are in a position where they could play a more active role to support the financing of treatments for their employees, since the majority of employees would have a corporate insurance scheme.

Read the full report to explore the barriers and solutions to equitable access in the Asia‑Pacific region

A full synopsis from the Zuellig Summit is available to download now. This report summarizes the key takeaways from all of the expert sessions:

• Best care anywhere: Achieving access for all to healthcare innovation in a complex region
  
  
• Partnering for health: Building strategic partnerships to achieve the goals for access and equity
  
  
• Trust your doctor? Securing trust in the healthcare system: how does this help drive access and equity?
  
  
• Health in your pocket: Leveraging digital solutions to empower community-centered and patient-centric care models
  
  
• The last mile to healthcare: Reimagining strategic supply chains to ensure equitable supply across and within markets
  
  
• Moving from “Wealth = Health” to “Health = Wealth”: Building value-based healthcare financing models that deliver equitable access

Supporting your Policy, Access, Value, and Evidence needs in the Asia-Pacific region

The Asia-Pacific region is characterized by its dynamic nature and rapidly evolving markets. These are critical to the future growth plans of our pharmaceutical and biotechnology clients, and we are leading many ground-breaking market access projects in the region.

PRMA Consulting, part of Fishawack Health, will help you bring out the best in your asset, using our extensive market access and disease area experience. Get in touch for a confidential conversation about your policy, access, value, and evidence needs.